Anstee QM - Search Results

1

Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment.

Govaere O, Cockell SJ, Zatorska M, Wonders K, Tiniakos D, Frey AM, Palmowksi P, Walker R, Porter A, Trost M, Anstee QM, Daly AK. Govaere O, et al. Among authors: anstee qm. Biochem Pharmacol. 2024 Oct;228:116249. doi: 10.1016/j.bcp.2024.116249. Epub 2024 Apr 30. Biochem Pharmacol. 2024. PMID: 38697308 Free article.

2

Genetics of alcoholic and nonalcoholic fatty liver disease.

Anstee QM, Daly AK, Day CP. Anstee QM, et al. Semin Liver Dis. 2011 May;31(2):128-46. doi: 10.1055/s-0031-1276643. Epub 2011 May 2. Semin Liver Dis. 2011. PMID: 21538280 Review.

3

The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.

Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK. Al-Serri A, et al. Among authors: anstee qm. J Hepatol. 2012 Feb;56(2):448-54. doi: 10.1016/j.jhep.2011.05.029. Epub 2011 Jul 12. J Hepatol. 2012. PMID: 21756849

4

Genetic modifiers of non-alcoholic fatty liver disease progression.

Anstee QM, Daly AK, Day CP. Anstee QM, et al. Biochim Biophys Acta. 2011 Nov;1812(11):1557-66. doi: 10.1016/j.bbadis.2011.07.017. Epub 2011 Aug 5. Biochim Biophys Acta. 2011. PMID: 21840395 Free article. Review.

5

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, Daly AK, Reeves HL, Anstee QM. Liu YL, et al. Among authors: anstee qm. J Hepatol. 2014 Jul;61(1):75-81. doi: 10.1016/j.jhep.2014.02.030. Epub 2014 Mar 6. J Hepatol. 2014. PMID: 24607626

6

Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease.

Aravinthan A, Mells G, Allison M, Leathart J, Kotronen A, Yki-Jarvinen H, Daly AK, Day CP, Anstee QM, Alexander G. Aravinthan A, et al. Among authors: anstee qm. Cell Cycle. 2014;13(9):1489-94. doi: 10.4161/cc.28471. Epub 2014 Mar 11. Cell Cycle. 2014. PMID: 24626178 Free PMC article.

7

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. Liu YL, et al. Among authors: anstee qm. Nat Commun. 2014 Jun 30;5:4309. doi: 10.1038/ncomms5309. Nat Commun. 2014. PMID: 24978903 Free PMC article.

8

TM6SF2 as a genetic risk factor for fibrosis.

Daly AK, Day CP, Liu YL, Anstee QM. Daly AK, et al. Among authors: anstee qm. Hepatology. 2015 Oct;62(4):1321. doi: 10.1002/hep.27656. Epub 2015 Jun 19. Hepatology. 2015. PMID: 25502834 No abstract available.

9

TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?

Kahali B, Liu YL, Daly AK, Day CP, Anstee QM, Speliotes EK. Kahali B, et al. Among authors: anstee qm. Gastroenterology. 2015 Apr;148(4):679-84. doi: 10.1053/j.gastro.2015.01.038. Epub 2015 Jan 29. Gastroenterology. 2015. PMID: 25639710 No abstract available.

10

Genetics of Alcoholic Liver Disease.

Anstee QM, Daly AK, Day CP. Anstee QM, et al. Semin Liver Dis. 2015 Nov;35(4):361-74. doi: 10.1055/s-0035-1567832. Epub 2015 Dec 16. Semin Liver Dis. 2015. PMID: 26676812 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters